BACKGROUND & AIMS: Irritable bowel syndrome (IBS) has been associated with mucosal dysfunction, mild inflammation, and altered colonic bacteria. We used microarray expression profiling of sigmoid colon mucosa to assess whether there are stably expressed sets of genes that suggest there are objective molecular biomarkers associated with IBS. METHODS: Gene expression profiling was performed using Human Genome U133 Plus 2.0 (Affymetrix) GeneChips with RNA from sigmoid colon mucosal biopsy specimens from 36 IBS patients and 25 healthy control subjects. Real-time quantitative polymerase chain reaction was used to confirm the data in 12 genes of interest. Statistical methods for microarray data were applied to search for differentially expressed genes, and to assess the stability of molecular signatures in IBS patients. RESULTS: Mucosal gene expression profiles were consistent across different sites within the sigmoid colon and were stable on repeat biopsy over approximately 3 months. Differentially expressed genes suggest functional alterations of several components of the host mucosal immune response to microbial pathogens. The most strikingly increased expression involved a yet uncharacterized gene, DKFZP564O0823. Identified specific genes suggest the hypothesis that molecular signatures may enable distinction of a subset of IBS patients from healthy controls. By using 75% of the biopsy specimens as a validation set to develop a gene profile, the test set (25%) was predicted correctly with approximately 70% accuracy. CONCLUSIONS: Mucosal gene expression analysis shows there are relatively stable alterations in colonic mucosal immunity in IBS. These molecular alterations provide the basis to test the hypothesis that objective biomarkers may be identified in IBS and enhance understanding of the disease.
BACKGROUND & AIMS:Irritable bowel syndrome (IBS) has been associated with mucosal dysfunction, mild inflammation, and altered colonic bacteria. We used microarray expression profiling of sigmoid colon mucosa to assess whether there are stably expressed sets of genes that suggest there are objective molecular biomarkers associated with IBS. METHODS: Gene expression profiling was performed using Human Genome U133 Plus 2.0 (Affymetrix) GeneChips with RNA from sigmoid colon mucosal biopsy specimens from 36 IBSpatients and 25 healthy control subjects. Real-time quantitative polymerase chain reaction was used to confirm the data in 12 genes of interest. Statistical methods for microarray data were applied to search for differentially expressed genes, and to assess the stability of molecular signatures in IBSpatients. RESULTS: Mucosal gene expression profiles were consistent across different sites within the sigmoid colon and were stable on repeat biopsy over approximately 3 months. Differentially expressed genes suggest functional alterations of several components of the host mucosal immune response to microbial pathogens. The most strikingly increased expression involved a yet uncharacterized gene, DKFZP564O0823. Identified specific genes suggest the hypothesis that molecular signatures may enable distinction of a subset of IBSpatients from healthy controls. By using 75% of the biopsy specimens as a validation set to develop a gene profile, the test set (25%) was predicted correctly with approximately 70% accuracy. CONCLUSIONS: Mucosal gene expression analysis shows there are relatively stable alterations in colonic mucosal immunity in IBS. These molecular alterations provide the basis to test the hypothesis that objective biomarkers may be identified in IBS and enhance understanding of the disease.
Authors: T Preckel; W P Fung-Leung; Z Cai; A Vitiello; L Salter-Cid; O Winqvist; T G Wolfe; M Von Herrath; A Angulo; P Ghazal; J D Lee; A M Fourie; Y Wu; J Pang; K Ngo; P A Peterson; K Früh; Y Yang Journal: Science Date: 1999-12-10 Impact factor: 47.728
Authors: Vinton S Chadwick; Wangxue Chen; Dairu Shu; Barbara Paulus; Peter Bethwaite; Andy Tie; Ian Wilson Journal: Gastroenterology Date: 2002-06 Impact factor: 22.682
Authors: Anne M Cornet; Emmanuel Hanon; Eric R Reiter; Marc Bruyninx; Viet Ha Nguyen; Benoît R Hennuy; Georges P Hennen; Jean L Closset Journal: Prostate Date: 2003-08-01 Impact factor: 4.104
Authors: K-A Gwee; S M Collins; N W Read; A Rajnakova; Y Deng; J C Graham; M W McKendrick; S M Moochhala Journal: Gut Date: 2003-04 Impact factor: 23.059
Authors: A Y Del Valle-Pinero; A C Martino; T J Taylor; B L Majors; N S Patel; M M Heitkemper; W A Henderson Journal: Neurogastroenterol Motil Date: 2011-09-23 Impact factor: 3.598
Authors: M Camilleri; P Carlson; S McKinzie; M Zucchelli; M D'Amato; I Busciglio; D Burton; A R Zinsmeister Journal: Neurogastroenterol Motil Date: 2011-07-14 Impact factor: 3.598
Authors: Michael Camilleri; Eric W Klee; Andrea Shin; Paula Carlson; Ying Li; Madhusudan Grover; Alan R Zinsmeister Journal: Am J Physiol Gastrointest Liver Physiol Date: 2013-11-07 Impact factor: 4.052
Authors: Michael Camilleri; Paula Carlson; Andres Acosta; Irene Busciglio; Asha A Nair; Simon J Gibbons; Gianrico Farrugia; Eric W Klee Journal: Am J Physiol Gastrointest Liver Physiol Date: 2014-04-24 Impact factor: 4.052
Authors: Aurore Carré; Ruy A N Louzada; Rodrigo S Fortunato; Rabii Ameziane-El-Hassani; Stanislas Morand; Vasily Ogryzko; Denise Pires de Carvalho; Helmut Grasberger; Thomas L Leto; Corinne Dupuy Journal: Antioxid Redox Signal Date: 2015-04-20 Impact factor: 8.401